1.RASSF1A: One of the thing cancer cell do is to Methylate some genes in order to block its path to death.
it
appears this gene is a critical door to shut or disable. It not only
decrease the significance of RAS and MAPK in the pathogenesis of tumor
that harbor this mutation. It also remove blockage to proliferation by
desensitizing the cell to the effect of P53, Cyclins. Desensitize
the cell to Death Receptor 6 and its Fas connection. RASSF1a,
demethylation is a valid target in ovarian cancer.
2.HNF1B: " Hepatocyte Nuclear Factor 1α (HNF1α) is an atypical
homeodomain-containing transcription factor that transactivates
liver-specific genes including albumin, α-1-antitrypsin and α- and
β-fibrinogen. Biallelic inactivating mutations of HNF1A have
been frequently identified in hepatocellular adenomas (HCA), rare benign
liver tumors usually developed in women under oral contraceptives, and
in rare cases of hepatocellular carcinomas developed in non-cirrhotic
liver. HNF1α-mutated HCA (H-HCA) are characterized by a marked steatosis
and show activation of glycolysis, lipogenesis, translational machinery
and mTOR pathway. We studied the consequences of HNF1α silencing in
hepatic cell lines, HepG2 and Hep3B and we reproduced most of the
deregulations identified in H-HCA."
(Laura Pelletier et al)
This
gene is the gene of differentiation for liver formation, it has the
structure of a CBF (core binding Factor) therefore has a subunit binding
the DNA, therefore silencing that portion, and another subunit having
locations for enzymatic proteins or molecular structures that directly
assume various functions intended by the cell (formation of
Albumin, alpha Antitrypsine, and Beta Fibrinogen).
Interestingly enough,
Steatosis is a prominent feature here. This structure and gene may be of
interest in LIPOSARCOMA?
DOES ACTIVATION OF MTOR DEMONSTRATED HERE
OPEN THE DOOR TO THE USE OF MTOR IN LIPOSARCOMA?
A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond
Showing posts with label MTOR expression. Show all posts
Showing posts with label MTOR expression. Show all posts
Friday, April 5, 2013
Nomenclature of 2 important genes in Ovarian cancer !
Labels:
crrbcm,
cyclins,
demethylation,
hepatocellular carcinoma,
hepatocyte nuclera factor,
HNF1A,
HNF1B,
liposarcoma,
MAPK,
methylation,
mtor,
MTOR expression,
ovarian cancer,
RAS,
RASSF1A,
steatosis
Thursday, March 7, 2013
Expression of MTOR can be quantified by the following:
Expression of MTOR can be quantified
by following PIK
Raptor
mLst8
Deptor
TORC2
SGK
Sin1
PRR5L
By Western Blot, Flowcytometry
by following PIK
Raptor
mLst8
Deptor
TORC2
SGK
Sin1
PRR5L
By Western Blot, Flowcytometry
Subscribe to:
Posts (Atom)